Although antigen-specific T cell responses remain to be critically evaluated, overall, these results suggest the triple combination of lower-dose panobinostat, venetoclax and anti-CD40 as a highly synergistic therapeutic strategy for long-term breast cancer control. The gene discussed is CD40; the disease is breast carcinoma.